IRCT20231119060108N1
Recruiting
Phase 2
Safety and Efficacy of Rituximab in patients with juvenile dermatomyositis (JDM) who were admitted at Mofid children hospital
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Juvenile dermatomyositis.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 7
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient under 16 years old
- •Patients with the diagnosis of dermatomyositis, which is confirmed based on the diagnosis criteria
Exclusion Criteria
- •Presence of concomitant diseases and overlap syndrome
- •Contraindications for rituximab injection
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTRheumatoid arthritisMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300
Active, not recruiting
Not Applicable
Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blockerTo investigate the efficacy of treatment with Rituximab (MabThera®) in patients with active RA whose current treatment with one or more TNF-blocker (Etanercept - Enbrel®, Infliximab – Remicade® or Adalimumab - Humira®) alone or in combination with MTX is insufficient measured by DAS28 activity index.EUCTR2006-004673-98-HURoche (Hungary) Ltd.20
Completed
Not Applicable
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
Completed
Phase 2
RECIPE TrialJPRN-jRCT2041180037Iijima Masahiro25